Blog
RSS FeedPosted by Michael Wonder on 17 Dec 2020
FDA updates list of off-patent, off-exclusivity drugs without an approved generic
17 December 2020 - Today, the U.S. FDA published an update to the “List of Off-Patent, Off-Exclusivity Drugs without an Approved ...
Posted by Michael Wonder on 17 Dec 2020
ICER publishes final evidence report and policy recommendations on new therapies for bladder cancer
17 December 2020 - Independent appraisal committee determines current evidence is adequate to demonstrate that nadofaragene firadenovec and oportuzumab monatox ...
Posted by Michael Wonder on 17 Dec 2020
PBS Expenditure and Prescriptions Report 2019-20
17 December 2020 - The PBS Expenditure and Prescriptions Report 1 July 2019 to 30 June 2020 is now available. ...
Posted by Michael Wonder on 02 Dec 2020
IQWiG publishes 1,000th report
2 December 2020 - In the 16th year of its existence, IQWiG has published its 1,000th report: a dossier assessment ...
Posted by Michael Wonder on 22 Nov 2020
ICER publishes final report and policy recommendations for haemophilia A therapies
20 November 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of emicizumab over factor ...
Posted by Michael Wonder on 13 Nov 2020
Public Summary Documents - PBAC July 2020 meeting
13 November 2020 - The Public Summary Documents (first time rejections and deferrals) from the July 2020 PBAC meeting are now ...
Posted by Michael Wonder on 12 Nov 2020
ICER releases draft evidence report on treatments for high cholesterol
12 November 2020 - Public comment period on preliminary draft now open until 11 December 2020; requests to make oral comment ...
Posted by Michael Wonder on 06 Nov 2020
ICER publishes evidence report on new therapies for bladder cancer
6 November 2020 - The evidence has significant limitations, and no firm estimate of net health benefit versus best supportive care ...
Posted by Michael Wonder on 06 Nov 2020
ICER publishes evidence report on digital therapeutics for opioid use disorder
6 November 2020 - The available evidence on the benefits of reSET-O, Connections, and DynamiCare has substantial limitations and can ...
Posted by Michael Wonder on 30 Oct 2020
Public Summary Documents - PBAC July 2020
30 October 2020 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2020 PBAC ...
Posted by Michael Wonder on 18 Oct 2020
ICER publishes final report and policy recommendations for targeted immune modulator therapies for ulcerative colitis
16 October 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of vedolizumab over adalimumab. ...
Posted by Michael Wonder on 17 Oct 2020
ICER publishes evidence report on therapies for haemophilia A
16 October 2020 - Emicizumab assessed as providing comparable or better clinical benefits when compared to common current dosing levels of ...
Posted by Michael Wonder on 11 Sep 2020
ICER publishes evidence report on targeted immune modulator therapies for ulcerative colitis
11 September 2020 - All assessed therapies provide significant health benefits, but even after rebates, all are priced at levels ...
Posted by Michael Wonder on 31 Aug 2020
ICER posts draft scoping document on lupus nephritis
31 August 2020 - Document open to public comment until 21 September 2020. ...
Posted by Michael Wonder on 28 Aug 2020
Public Summary Documents - May 2020 PBAC meeting
28 August 2020 - There is actually only one Public Summary Document from the May 2020 PBAC meeting. ...